| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/13/2009 | US20090202538 F11 receptor (f11r) antagonists as therapeutic agents |
| 08/13/2009 | US20090202537 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 08/13/2009 | US20090202536 Antibody-drug conjugates and methods |
| 08/13/2009 | US20090202535 Method for neutralizing effects of sPLA2 |
| 08/13/2009 | US20090202534 Compositions and methods for modulating immune responses |
| 08/13/2009 | US20090202533 Treatment and prophylaxis of th2 mediated disorders |
| 08/13/2009 | US20090202532 High Functional Bispecific Antibody |
| 08/13/2009 | US20090202531 Uses of anti-cd40 antibodies |
| 08/13/2009 | US20090202530 Identification of Tumor-Associated Antigens for Diagnosis and Therapy |
| 08/13/2009 | US20090202529 Use of egfr inhibitors to prevent or treat obesity |
| 08/13/2009 | US20090202528 Surface-Located Streptococcus Pneumoniae Polypeptides |
| 08/13/2009 | US20090202527 Treatment for multiple sclerosis |
| 08/13/2009 | US20090202526 Agonist anti-trkc antibodies and methods using same |
| 08/13/2009 | US20090202525 Dihydroisoindolones as allosteric modulators of glucokinase |
| 08/13/2009 | US20090202524 Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
| 08/13/2009 | US20090202523 Antibodies against a peptide epitope of apoliporotein b |
| 08/13/2009 | US20090202522 Use of goat serum for veterinary treatment |
| 08/13/2009 | US20090202521 Bifunctional Polyazamacrocyclic Chelating Agents |
| 08/13/2009 | US20090202520 Treatment and diagnostic methods for fibrosis related disorders |
| 08/13/2009 | US20090202519 Compositions and methods for treating gram positive bacterial infection in a mammalian subject |
| 08/13/2009 | US20090202518 Treatment of sepsis and inflammation with alpha2A Adrenergic antagonists |
| 08/13/2009 | US20090202506 loading antigen presenting cells from a subject; loading antigen presenting cells (APC's) having Class I MHC (major histocompatibility factor) molecules with T cell epitopes; culturing CD8+ T cells with APC's; expanding in culture; for allergic asthma |
| 08/13/2009 | US20090202504 Methods for the detection and prognosis of breast tumors |
| 08/13/2009 | US20090202487 Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology |
| 08/13/2009 | US20090202482 Prevention and Treatment of HCV Infection Employing Antibodies Directed Against Conformational and Linear Epitopes |
| 08/13/2009 | US20090202475 Compositions and methods for treatment of microbial disorders |
| 08/13/2009 | US20090202439 Methods for treatment of angiogenesis |
| 08/13/2009 | US20090202438 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 08/13/2009 | US20090202437 Therapeutic Use of Lpi, a Staphylococcal Lectin Pathway Inhibitor in Inflammatory diseases |
| 08/13/2009 | US20090202433 Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses |
| 08/13/2009 | US20090202432 Treatment and prophylaxis of amyloidosis |
| 08/13/2009 | US20090202431 Stem-like cells in bone sarcomas |
| 08/13/2009 | US20090202430 Composition for cytocompatible, injectable, self-gelling polysaccharide solutions for encapsulating and delivering live cells or biologically active factors |
| 08/13/2009 | US20090202039 Methods for Sterilizing Biological Materials Containing Non-Aqueous Solvents |
| 08/13/2009 | CA2714413A1 Antibody capable of binding specifically to ab-oligomer, and use thereof |
| 08/13/2009 | CA2714071A1 Alpha 5 - beta 1 antibodies and their uses |
| 08/13/2009 | CA2713933A1 Camptothecin-binding moiety conjugates |
| 08/13/2009 | CA2713786A1 Anti trka antibodies and derivatives thereof |
| 08/13/2009 | CA2713504A1 Anti-cd79b antibodies and immunoconjugates and methods of use |
| 08/13/2009 | CA2713342A1 Compositions and methods for crystallizing antibody fragments |
| 08/13/2009 | CA2713178A1 Influenza b vaccines |
| 08/13/2009 | CA2712965A1 Antigen-binding polypeptides against cartilage degeneration |
| 08/13/2009 | CA2712080A1 Breaking immunological tolerance with a genetically encoded unnatural amino acid |
| 08/13/2009 | CA2711798A1 Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| 08/13/2009 | CA2711794A1 1d05 pcsk9 antagonists |
| 08/13/2009 | CA2711791A1 1b20 pcsk9 antagonists |
| 08/13/2009 | CA2709925A1 Leporipoxvirus-derived vaccine vectors |
| 08/13/2009 | CA2708668A1 Novel vaccines against multiple subtypes of dengue virus |
| 08/12/2009 | EP2088197A2 Haemophilus influenzae antigens and corresponding DNA fragments |
| 08/12/2009 | EP2088159A1 Antibody recognizing c-domain of midkine |
| 08/12/2009 | EP2088158A2 Monoclonal antibody against the CCR5 chemokine receptor |
| 08/12/2009 | EP2088155A1 Hetero-oligomeric HIV envelope proteins |
| 08/12/2009 | EP2087908A1 Antibodies to opgl |
| 08/12/2009 | EP2087907A2 Method and system to remove cytokine inhibitor in patients |
| 08/12/2009 | EP2087906A1 Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines |
| 08/12/2009 | EP2087904A1 Therapeutic use of peptides derived from Bcl-XL protein in cancer patients |
| 08/12/2009 | EP2087898A1 A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis |
| 08/12/2009 | EP2087128A2 Compositions and methods for immunodominant antigens |
| 08/12/2009 | EP2087103A1 Cancerous disease modifying antibodies |
| 08/12/2009 | EP2087095A1 In vitro cultivation of helicobacter species |
| 08/12/2009 | EP2087008A1 TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6 |
| 08/12/2009 | EP2087007A2 Agonist trkb antibodies and uses thereof |
| 08/12/2009 | EP2087005A2 Compounds |
| 08/12/2009 | EP2087004A2 A novel passive vaccine for candida infections |
| 08/12/2009 | EP2087002A2 Compositions and methods for binding sphingosine-1-phosphate |
| 08/12/2009 | EP2086584A2 Antibodies that bind cxcr7 epitopes |
| 08/12/2009 | EP2086583A2 Fully human anti-vegf antibodies and methods of using |
| 08/12/2009 | EP2086582A1 Vaccine comprising an oil in water emulsion adjuvant |
| 08/12/2009 | EP2086581A2 Stabilization of vaccines by lyophilization |
| 08/12/2009 | EP2086580A2 Prime boost canine leishmania vaccine |
| 08/12/2009 | EP2086579A2 Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine |
| 08/12/2009 | EP2086578A1 Use of clostridium perfringens type c bacterium for the manufacture of a vaccine |
| 08/12/2009 | EP2086577A2 Conjugates of plasmodium falciparum surface proteins as malaria vaccines |
| 08/12/2009 | EP2086576A2 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| 08/12/2009 | EP2086575A2 Light-mediated anti-cell proliferative compositions and methods |
| 08/12/2009 | EP2086574A2 Methods of treating disorders associated with fat storage |
| 08/12/2009 | EP2086573A2 Cerebrospinal fluid purification system |
| 08/12/2009 | EP2086526A2 Induction of an immune response against dengue virus using prime-boost approach |
| 08/12/2009 | EP1896588B1 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF |
| 08/12/2009 | EP1880733A4 Method for increasing longevity of a human being and animals |
| 08/12/2009 | EP1755662B1 Combined meningococcal conjugates with common carrier protein |
| 08/12/2009 | EP1675579B1 Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
| 08/12/2009 | EP1576011B1 Inhibition of il-17 production |
| 08/12/2009 | EP1559432B1 Hm1.24-utilizing cancer vaccines |
| 08/12/2009 | EP1409645B1 Probiotic lactobacillus salivarius strains |
| 08/12/2009 | EP1149111B1 Method and composition for angiogenesis inhibition |
| 08/12/2009 | EP1123711B9 Attenuated toxins as adjuvants |
| 08/12/2009 | EP1030675B1 Treatment of hematologic disorders |
| 08/12/2009 | EP0771322B9 Abundant extracellular products and methods for their production and use |
| 08/12/2009 | CN101506357A Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders |
| 08/12/2009 | CN101506239A Antihuman alpha9 integrin antibody and use of the same |
| 08/12/2009 | CN101506238A Methods and compositions with enhanced therapeutic activity |
| 08/12/2009 | CN101506237A Anti-C5aR antibodies with improved properties |
| 08/12/2009 | CN101506236A Monoclonal antibodies against amyloid beta protein and uses thereof |
| 08/12/2009 | CN101505796A Soft tissue repair and regeneration using stem cell products |
| 08/12/2009 | CN101505795A Composition for modulating the expression of cell adhesion molecules |
| 08/12/2009 | CN101505794A scFV antibodies which pass epithelial and/or endothelial layers |
| 08/12/2009 | CN101505793A Anti-C35 antibodies for treating cancer |
| 08/12/2009 | CN101505792A Tumor therapy with an anti-VEGF antibody |
| 08/12/2009 | CN101505791A Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |